Skip to main content
. Author manuscript; available in PMC: 2010 Aug 23.
Published in final edited form as: Arch Neurol. 2008 May 12;65(7):896–905. doi: 10.1001/archneur.2008.65.7.nct70006

Table 4.

Longitudinal Effect of Treatment on Cognitive Function, Excluding Measurements Associated With Incident Dementia

Measure Celecoxib vs Placebo
 Naproxen Sodium vs Placebo
β (95% Confidence Interval) P Value β (95% Confidence Interval) P Value
Global summary score −0.004 (−0.04 to 0.03) .84 −0.03 (−0.07 to 0.01) .09
Adjusted 3MS-E score −0.20 (−0.47 to 0.07) .14 −0.19 (−0.47 to 0.09) .19
GVF score −0.23 (−0.69 to 0.23) .32 −0.43 (−0.90 to 0.03) .07
RBMT delayed recall score −0.06 (−0.29 to 0.18) .64 −0.13 (−0.37 to 0.11) .28
BVMT-R delayed recall score 0.05 (−0.14 to 0.23) .62 −0.07 (−0.26 to 0.12) .45
Adjusted HVLT-R trial 4 score 0.12 (−0.06 to 0.30) .2 −0.04 (−0.23 to 0.16) .7
Digit Span score, forward −0.05 (−0.19 to 0.09) .48 −0.03 (−0.17 to 0.11) .69
Digit Span score, backward 0.03 (−0.11 to 0.18) .64 −0.09 (−0.23 to 0.05) .22

Abbreviations: BVMT-R, Brief Visuospatial Memory Test–Revised; GVF, generative verbal fluency; HVLT-R, Hopkins Verbal Learning Test–Revised; RBMT, Rivermead Behavioral Memory Test; 3MS-E, Modified Mini-Mental State Examination.